Microvascular dysfunction in the heart and brain, cerebral microvascular dysfunction, cardiac microvascular dysfunction, heart failure and vascular cognitive impairment Circulatory System Heart failure, vascular cognitive impairment, aortic stenosis
Conditions
Interventions
Four cohorts of participants will be recruited from the three trial participating centres. Participant cohorts have either clinical HFpEF or asymptomatic cardiac structural and/or functional alteratio
Sponsors
European Commission
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The MAASTRICHT cohort 1. Cognitive complaints 2. Signs of cerebral small vessel disease on brain MRI defined as at least Fazekas grade > 1 3. < 26 on the Montreal Cognitive Assessment 4. Aged 60 to 80 years The PAMPLONA-HFpEF cohort 1. Clinical symptoms of HFpEF of hypertensive or valvular origin (classified according to the current guidelines of the European Society of Cardiology, or ESC) 2. Structural and/or functional alterations such as left ventricular hypertrophy, left atrial dilation, and diastolic dysfunction but clinical symptoms not yet developed 3. Aged 45-85 years The RELIEF-AS II cohort 1. Severe aortic stenosis 2. Suitable for aortic valve replacement surgery 3. 50 to 85 years The UCL BIRTH cohort 1. Aged 60-80 years
Exclusion criteria
Exclusion criteria: 1. Pregnancy and/or lactation 2. eGFR 50% stenosis or prior myocardial infarction 4. LVEF 50% stenosis
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1. Identification of microvascular rarefaction as a predictive disease measurement in diastolic heart failure (HFpEF) and/or vascular cognitive impairment from MRI measurements at baseline 2. Development of alternate non-invasive measurements of microvascular rarefaction or dysfunction using Glycocheck machine, circulating biomarkers and OCT-angiography measurements at baseline | — |
Primary
| Measure | Time frame |
|---|---|
| First clinical confirmation of microvascular function measurements using state-of-the-art MRI measurements at baseline in a large patient cohort | — |
Countries
England, Netherlands, Spain, United Kingdom
Outcome results
None listed